Abbott Laboratories reports results for the quarter ended June 30 - Earnings Summary

• Abbott Laboratories ABT reported quarterly adjusted earnings of $1.26​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.14. The mean expectation of twenty four analysts for the quarter was for earnings of $1.25 per share. Wall Street expected results to range from $1.24 to $1.28 per share.

• Revenue rose 7.4% to $11.14 billion from a year ago; analysts expected $11.07 billion.

• Abbott Laboratories's reported EPS for the quarter was $1.01​.

• The company reported quarterly net income of $1.78 billion.

• Abbott Laboratories shares had fallen by 3.1% this quarter and gained 16.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.3% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Abbott Laboratories is $144.50, about 8.8% above its last closing price of $131.74

This summary was machine generated from LSEG data July 17 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)